Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
Carlos Doti, VP US Medical Affairs Oncology at AstraZeneca, shared on LinkedIn:
”As I reflect on another ASH, I’m reminded why this meeting is such a powerful close to the year – where science, collaboration and patient experiences come together to shape the future of hematology.
This year, I participated in two meaningful AstraZeneca events:
Moderating our annual Patient Advocacy Exchange panel with advocacy leaders focused on shared decision-making and patient navigation, discussing how to break down barriers and promote equitable access to care.
Hosting our first-ever AZHemeTalks – a live, pop-up series – at our booth, where I spoke with a clinical trial patient and her doctor about how treatment choices impact daily life.
The video here shows how we brought this activation to life through 4 expert panels focused on the treatment landscape in leukemia, lymphomas and multiple myeloma.”
Stay updated with Hemostasis Today.
-
Apr 5, 2026, 08:19Alan Nurden: Disrupting Pathogenic Alleles in VWD Through Gene Editing
-
Apr 5, 2026, 05:32Preeti Sinha: Molecular Mechanisms of Atherosclerosis
-
Apr 5, 2026, 05:28Alessandra Bosch: Exploring Haemostasis in Children
-
Apr 5, 2026, 05:19Chris Centeno: What If You Could Delay Aging and Improve Cognition with Regular Blood Therapy?
-
Apr 4, 2026, 18:08Anirban Sen Gupta: Dante Disharoon’s Research on PlateChek Featured on JTH April 2026 Cover
-
Apr 4, 2026, 18:06Domenico Girelli: WHO 2024 Guidelines Reveal Higher Global Anemia Burden and Epidemiological Shift
-
Apr 4, 2026, 18:04Fotios Barkas: Exploring The Bidirectional Relationship Between Frailty and Stroke
-
Apr 4, 2026, 17:56Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
-
Apr 4, 2026, 17:55Julian Kyoung-Ryul Chun: The Largest Dataset on Embolic Complications after AF Is Out